

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
14 April 2022 (14.04.2022)



(10) International Publication Number  
**WO 2022/077021 A1**

(51) International Patent Classification:  
*A61P 17/00* (2006.01) *C07K 16/28* (2006.01)  
*A61P 37/00* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/US2021/071779

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:  
07 October 2021 (07.10.2021)

(25) Filing Language: English

**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(26) Publication Language: English

(30) Priority Data:  
63/090,055 09 October 2020 (09.10.2020) US

(71) Applicants: **PFIZER INC.** [US/US]; 235 East 42nd Street,  
New York, New York 10017 (US). **CHILDREN'S MEDICAL CENTER CORPORATION** [US/US]; 55 Shattuck  
St., Boston, Massachusetts 02115 (US).

(72) Inventors: **WINAU, Florian**; 293 Shawmut Ave., Boston,  
Massachusetts 02118 (US). **KOVALENKO, Oleg V.**; c/  
o Pfizer Inc., 235 East 42nd Street, New York, New York  
10017 (US). **CHANG, Chew Shun**; c/o Pfizer Inc., 235  
East 42nd Street, New York, New York 10017 (US). **WU,  
Di**; c/o Pfizer Inc., 235 East 42nd Street, New York, New  
York 10017 (US). **MARZE, Nicholas Andrew**; c/o Pfizer  
Inc., 235 East 42nd Street, New York, New York 10017  
(US). **CHIANG, Shian-Huey**; c/o Pfizer Inc., 235 East  
42nd Street, New York, New York 10017 (US).

(74) Agent: **BRUNER, J. Kyle**; Norton Rose Fulbright US LLP,  
98 San Jacinto Blvd, Suite 1100, Austin, Texas 78701 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CD1a ANTIBODIES AND USES THEREOF

(57) Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

WO 2022/077021 A1